证券代码：688443 证券简称：智翔金泰 公告编号：2025-033

Core Points - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial application of its product GR1802 injection for the indication of seasonal allergic rhinitis in adolescents [1][2] Group 1: Drug Information - The drug GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody targeting IL-4Rα, which specifically binds to the cell surface human IL-4Rα, blocking the binding of IL-4 and IL-13, thereby inhibiting downstream STAT6 phosphorylation and CD23 upregulation, thus suppressing Th2-type inflammatory responses mediated by IL-4 or IL-13 [2] - GR1802 injection has previously received clinical trial approval for multiple indications, including moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, allergic rhinitis, currently in phase III clinical trials, and asthma in phase II clinical trials, with atopic dermatitis in children/adolescents in phase Ib/II clinical trials [2] Group 2: Market Context - As of the date of this announcement, only two other drugs targeting the same receptor have been approved for marketing in China [3]